Peripheral T-cell lymphoma

Francine M. Foss, Pier Luigi Zinzani, Julie Marie Vose, Randy D. Gascoyne, Steven T. Rosen, Kensei Tobinai

Research output: Contribution to journalReview article

187 Citations (Scopus)

Abstract

Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of clinically aggressive diseases associated with poor outcome. Studies that focus specifically on PTCL are emerging, with the ultimate goal of improved understanding of disease biology and the development of more effective therapies. However, one of the difficulties in classifying and studying treatment options in clinical trials is the rarity of these subtypes. Various groups have developed lymphoma classifications over the years, including the World Health Organization, which updated its classification in 2008. This article briefly reviews the major lymphoma classification schema, highlights contributions made by the collaborative International PTCL Project, discusses prognostic issues and gene expression profiling, and outlines therapeutic approaches to PTCL. These include the standard chemotherapeutic regimens and other modalities incorporating antifolates, conjugates, histone deacetylase inhibitors, monoclonal antibodies, nucleoside analogs, proteasome inhibitors, and signaling inhibitors. As this review emphasizes, the problem has now evolved into an abundance of drugs and too few patients available to test them. Collaborative groups will aid in future efforts to find the best treatment strategies to improve the outcome for patients with PTCL.

Original languageEnglish (US)
Pages (from-to)6756-6767
Number of pages12
JournalBlood
Volume117
Issue number25
DOIs
StatePublished - Jun 23 2011

Fingerprint

Peripheral T-Cell Lymphoma
T-cells
Lymphoma
Folic Acid Antagonists
Proteasome Inhibitors
Histone Deacetylase Inhibitors
Gene Expression Profiling
Therapeutics
Nucleosides
Gene expression
Monoclonal Antibodies
Health
Clinical Trials
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Foss, F. M., Zinzani, P. L., Vose, J. M., Gascoyne, R. D., Rosen, S. T., & Tobinai, K. (2011). Peripheral T-cell lymphoma. Blood, 117(25), 6756-6767. https://doi.org/10.1182/blood-2010-05-231548

Peripheral T-cell lymphoma. / Foss, Francine M.; Zinzani, Pier Luigi; Vose, Julie Marie; Gascoyne, Randy D.; Rosen, Steven T.; Tobinai, Kensei.

In: Blood, Vol. 117, No. 25, 23.06.2011, p. 6756-6767.

Research output: Contribution to journalReview article

Foss, FM, Zinzani, PL, Vose, JM, Gascoyne, RD, Rosen, ST & Tobinai, K 2011, 'Peripheral T-cell lymphoma', Blood, vol. 117, no. 25, pp. 6756-6767. https://doi.org/10.1182/blood-2010-05-231548
Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma. Blood. 2011 Jun 23;117(25):6756-6767. https://doi.org/10.1182/blood-2010-05-231548
Foss, Francine M. ; Zinzani, Pier Luigi ; Vose, Julie Marie ; Gascoyne, Randy D. ; Rosen, Steven T. ; Tobinai, Kensei. / Peripheral T-cell lymphoma. In: Blood. 2011 ; Vol. 117, No. 25. pp. 6756-6767.
@article{2bff657b7df84f428b7e3bc5a1d7f0e2,
title = "Peripheral T-cell lymphoma",
abstract = "Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of clinically aggressive diseases associated with poor outcome. Studies that focus specifically on PTCL are emerging, with the ultimate goal of improved understanding of disease biology and the development of more effective therapies. However, one of the difficulties in classifying and studying treatment options in clinical trials is the rarity of these subtypes. Various groups have developed lymphoma classifications over the years, including the World Health Organization, which updated its classification in 2008. This article briefly reviews the major lymphoma classification schema, highlights contributions made by the collaborative International PTCL Project, discusses prognostic issues and gene expression profiling, and outlines therapeutic approaches to PTCL. These include the standard chemotherapeutic regimens and other modalities incorporating antifolates, conjugates, histone deacetylase inhibitors, monoclonal antibodies, nucleoside analogs, proteasome inhibitors, and signaling inhibitors. As this review emphasizes, the problem has now evolved into an abundance of drugs and too few patients available to test them. Collaborative groups will aid in future efforts to find the best treatment strategies to improve the outcome for patients with PTCL.",
author = "Foss, {Francine M.} and Zinzani, {Pier Luigi} and Vose, {Julie Marie} and Gascoyne, {Randy D.} and Rosen, {Steven T.} and Kensei Tobinai",
year = "2011",
month = "6",
day = "23",
doi = "10.1182/blood-2010-05-231548",
language = "English (US)",
volume = "117",
pages = "6756--6767",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "25",

}

TY - JOUR

T1 - Peripheral T-cell lymphoma

AU - Foss, Francine M.

AU - Zinzani, Pier Luigi

AU - Vose, Julie Marie

AU - Gascoyne, Randy D.

AU - Rosen, Steven T.

AU - Tobinai, Kensei

PY - 2011/6/23

Y1 - 2011/6/23

N2 - Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of clinically aggressive diseases associated with poor outcome. Studies that focus specifically on PTCL are emerging, with the ultimate goal of improved understanding of disease biology and the development of more effective therapies. However, one of the difficulties in classifying and studying treatment options in clinical trials is the rarity of these subtypes. Various groups have developed lymphoma classifications over the years, including the World Health Organization, which updated its classification in 2008. This article briefly reviews the major lymphoma classification schema, highlights contributions made by the collaborative International PTCL Project, discusses prognostic issues and gene expression profiling, and outlines therapeutic approaches to PTCL. These include the standard chemotherapeutic regimens and other modalities incorporating antifolates, conjugates, histone deacetylase inhibitors, monoclonal antibodies, nucleoside analogs, proteasome inhibitors, and signaling inhibitors. As this review emphasizes, the problem has now evolved into an abundance of drugs and too few patients available to test them. Collaborative groups will aid in future efforts to find the best treatment strategies to improve the outcome for patients with PTCL.

AB - Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of clinically aggressive diseases associated with poor outcome. Studies that focus specifically on PTCL are emerging, with the ultimate goal of improved understanding of disease biology and the development of more effective therapies. However, one of the difficulties in classifying and studying treatment options in clinical trials is the rarity of these subtypes. Various groups have developed lymphoma classifications over the years, including the World Health Organization, which updated its classification in 2008. This article briefly reviews the major lymphoma classification schema, highlights contributions made by the collaborative International PTCL Project, discusses prognostic issues and gene expression profiling, and outlines therapeutic approaches to PTCL. These include the standard chemotherapeutic regimens and other modalities incorporating antifolates, conjugates, histone deacetylase inhibitors, monoclonal antibodies, nucleoside analogs, proteasome inhibitors, and signaling inhibitors. As this review emphasizes, the problem has now evolved into an abundance of drugs and too few patients available to test them. Collaborative groups will aid in future efforts to find the best treatment strategies to improve the outcome for patients with PTCL.

UR - http://www.scopus.com/inward/record.url?scp=79959503595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959503595&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-05-231548

DO - 10.1182/blood-2010-05-231548

M3 - Review article

C2 - 21493798

AN - SCOPUS:79959503595

VL - 117

SP - 6756

EP - 6767

JO - Blood

JF - Blood

SN - 0006-4971

IS - 25

ER -